Last reviewed · How we verify
D326(placebo)
D326 is a placebo control with no active pharmacological mechanism.
At a glance
| Generic name | D326(placebo) |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, D326 contains no active pharmaceutical ingredient and produces no direct molecular or therapeutic effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of active investigational drugs by isolating the true drug effect from placebo response.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of CKD-386 (PHASE3)
- Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D326(placebo) CI brief — competitive landscape report
- D326(placebo) updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI